● Recruiting

MB-105 in Patients With CD5 Positive T-cell Lymphoma

Condition: Lymphoma, T-Cell · Sponsor: March Biosciences Inc

PhasePhase 2

Planned participants46

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

This is a single arm, two-stage, Phase 2, open-label, multicenter study of MB-105 in patients with CD5 Positive (CD5+) Relapsed / Refractory T-cell Lymphoma (r/r TCL). This study will apply a Simon two-stage optimal design.

This description comes directly from the study's public registry record.

Talk to the study team

Federica Giordano, Ph.D. · 7138980838 · clinicaltrials@march.bio

Always discuss trial participation with your own doctor first.

Locations (12)

University of San Diego (UCSD)-Moores Cancer Center	San Diego, California, United States	Recruiting
SCRI - Colorado Blood Cancer Institute (CBCI)	Denver, Colorado, United States	Not Yet Recruiting
Moffitt Cancer Center Magnolia Campus	Tampa, Florida, United States	Recruiting
University of Iowa	Iowa City, Iowa, United States	Recruiting
Massachusetts General Hospital	Boston, Massachusetts, United States	Recruiting
University of Nebraska	Omaha, Nebraska, United States	Recruiting
Memorial Sloan Kettering Cancer Center	New York, New York, United States	Recruiting
University of North Carolina at Chapel Hill	Chapel Hill, North Carolina, United States	Recruiting
Cleveland Clinic	Cleveland, Ohio, United States	Not Yet Recruiting
Oregan Health & Science University	Portland, Oregon, United States	Not Yet Recruiting
Baylor College of Medicine	Houston, Texas, United States	Recruiting
MD Anderson Cancer Center	Houston, Texas, United States	Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06534060